Vivos Therapeutics (NASDAQ:VVOS) has announced positive results from a seven-month, multi-site pilot of its new provider-based marketing and distribution model.
The medical technology firm recently unveiled its new marketing and distribution model under which it seeks to drive revenue through partnerships with dentists and sleep treatment providers to offer patients with obstructive sleep apnea (OSA) a range of evidence-based treatment options, including Vivos’ FDA-cleared CARE oral medical devices, oral appliances, and additive adjunctive therapies and methods.
The pilot program was carried out across seven dental offices and one ear, nose and throat specialist office across several states, involving 76 adult patients.
It showed that 79% of newly diagnosed adult OSA patients chose Vivos’ oral appliance therapy over either continuous positive airway pressure (CPAP) machines or choosing to do nothing.
Further, 5% declined all treatment options, and 16% chose to investigate CPAP as an option before making a final decision. No patients in the pilot program opted for surgical or neurostimulation implant options.
A smaller cohort of 23 pediatric patients with orofacial and developmental abnormalities potentially tied to sleep and breathing disorders such as tongue ties, mouth breathing, malocclusion and smaller jaws were also evaluated and treated using the company’s orthodontic guided growth appliances and oral myofunctional therapy.
“The message is clear: when Vivos teams up with medical professionals who treat OSA, and when patients are fully informed as to the health risks of untreated OSA and the full range of treatment options available in an open and transparent manner, they overwhelmingly chose Vivos’ CARE oral medical devices,” Vivos CEO Kirk Huntsman said in a statement.
“As we continue to expand beyond dentists and move more directly and vertically into affiliations and collaborations with medical specialists, functional medicine doctors, and other sleep-related healthcare practitioners, we expect this to positively impact our new case starts, revenue growth and gross profit.”
Investors welcomed the news, sending Vivos’ shares almost 7% higher premarket.